Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis

Tropical Medicine and International Health

Volumn 8, Issue 9, 2003, Pages 820-831

  Twum Danso, Nana A Y ^a   Meredith, Stefanie E O ^a  

^a Mectizan Donation Program   (United States)

Author keywords

Adverse drug reaction reporting systems; Cameroon; Community health services; Ivermectin; Loiasis; Onchocerciasis

Indexed keywords

IVERMECTIN;

DISEASE INCIDENCE; DISEASE TREATMENT; DRUG PRESCRIBING; ONCHOCERCIASIS;

ADULT; AFRICA; ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; HUMAN; INCIDENCE; INFECTION RATE; INFECTION RISK; LOA LOA; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MICROFILARIASIS; ONCHOCERCIASIS; PREVENTIVE HEALTH SERVICE; RELIABILITY; RISK FACTOR;

ADOLESCENT; ADULT; AGED; CAMEROON; CHILD; ENDEMIC DISEASES; FEMALE; FILARICIDES; HOSPITALIZATION; HUMANS; IVERMECTIN; LOIASIS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; ONCHOCERCIASIS; PROGNOSIS; RETROSPECTIVE STUDIES;

CAMEROON;

LOA LOA;

EID: 0042736852     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3156.2003.01091.x     Document Type: Article

References (34)

1. Anonymous (1996) Central Nervous System (CNS) Complications of Loiasis and Adverse CNS Events Following Treatment: Report of an Invited Consultation. Mectizan® Donation Program, Atlanta, 1995.
2. Awadzi K, Dadzie KY, Shulz-Key H, Haddock DR, Gilles HM & Aziz MA (1985) The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis. Annals of Tropical Medicine & Parasitology 79, 63-78.
3. Boussinesq M & Gardon J (1997) Prevalences of Loa loa microfilaremia throughout the area endemic for the infection. Annals of Tropical Medicine & Parasitology 91, 573-589.
4. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P & Chippaux JP (1998) Three probable cases of Loa Loa encephalopathy following ivermectin treatment for onchocerciasis. American Journal of Tropical Medicine and Hygiene 58, 461-469.
5. Boussinesq M, Gardon J, Kamgno J, Pion SD, Gardon-Wendel N & Chippaux JP (2001) Relationships between the prevalence and intensity of Loa loa infection in the Central province of Cameroon. Annals of Tropical Medicine & Parasitology 95, 495-507.
6. De Sole G, Remme J, Awadzi K et al. (1989) Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bulletin of the World Health Organization 67, 707-719.
7. Ducorps M, Gardon-Wendel N, Ranque S et al. (1995) Effets secondaires du traitement de la loase hypermicrofilaremique par l'ivermectine. Bulletin de la Societe de Pathologie Exotique et de ses Filiales 88, 105-112.
8. Duong TH, Kombila M, Ferrer A, Bureau P, Gaxotte P, Richard-Lenoble D (1997) Reduced Loa loa microfilaria count ten to twelve months after a single dose of invermectin. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 592-593.
9. Fobi G, Gardon J, Santiago M, Ngangue D, Gardon-Wendel N & Boussinesq M (2000) Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia. Ophthalmic Epidemiology 7, 27-39.
10. Gardon J, Gardon-Wendel N, Ngangue D, Kamgno J, Chippaux J-P & Boussinesq M (1997) Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350, 18-20.
11. Haselow N, Evini C, Akame J & Akongo S (2003) Programmatic issues in relation to serious adverse effects following ivermectin treatment in areas co-endemic for onchocerciasis and loiasis. Filaria Journal 2 (in press).
12. Hougard J-M, Alley ES, Yameogo L, Dadzie KY & Boatin BA (2001) Eliminating onchocerciasis after 14 years of vector control: a proved strategy. Journal of Infectious Diseases 184, 497-503.
13. Kombila M, Duoung TH, Ferrer A et al. (1998) Short- and long-term action of multiple doses of ivermectin on loiasis microfilaremia. American Journal of Tropical Medicine and Hygiene 58, 458-460.
14. Lankas GR, Gordon LR (1989) Toxicology. In Ivermectin and Abamectin (ed. W Campbell) Springer-Verlag, New York, pp. 89-112.
15. Martin-Prevel Y, Cosnefroy J-Y, Tshipamba P, Ngari P, Chodkewitz JA & Pinder M (1993) Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. American Journal of Tropical Medicine and Hygiene 48, 186-192.
16. Mealey KL, Bentjen SA, Gay JM & Cantor GH (2001) Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr 1gene. Pharmacogenetics 11, 727-733.
17. Mectizan® Donation Program (1998) Community-Based Mass Treatment of Onchocerciasis: Program Information. Mectizan® Donation Program, Atlanta, USA.
18. Mectizan® Expert Committee (2000) Recommendations for the Treatment of Onchocerciasis with Mectizan in Areas Co-endemic for Onchocerciasis and Loiasis. Mectizan® Donation Program, Atlanta, USA.
19. Ndonko FT (1999) Review of Community-based System for the Management of Side Effects to Mectizan® in the Okola Health District, Central Province of Cameroon. Ministry of Public Health-Cameroon, Yaoundé.
20. Oladepo O, Brieger WR, Otusanya S, Kale O, Offiong S & Titiloye M (1997) Farm land size and onchocerciasis status of peasant farmers in south-western Nigeria. Tropical Medicine & International Health 2, 334-340.
21. Schinkel AH, Smit JJM, van Tellingen O et al. (1994) Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502.
22. Takougang I, Meremikwu M, Wandji S et al. (2002) Rapid assessment method for prevalence and intensity of Loa loa infection. Bulletin of the World Health Organization 80, 852-858.
23. Tamai I & Tsuji A (2000) Transporter-mediated permeation of drugs across the blood-brain barrier. Journal of Pharmaceutical Sciences 89, 1371-1388.
24. Tatsuta T, Naito M, Oh-hara T, Sugawara I & Tsuruo T (1992) Functional involvement of P-glycoprotein in blood-brain barrier. Journal of Biological Chemistry 28, 20 383-20 391.
25. Thomson MC, Obsomer V, Dunne M, Connor SJ & Molyneux DH (2000) Satellite mapping of Loa loa prevalence in relation to ivermectin use in west and central Africa. Lancet 356, 1077-1078.
26. Tsuji A, Terasaki T, Takabatake Y et al. (1992) P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sciences 51, 1427-1437.
27. Twum-Danso NAY (2003a) Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria Journal 2 (in press).
28. Twum-Danso NAY (2003b) Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria Journal 2 (in press).
29. Van Bogaert L, Dubois A, Janssens PG, Radermecker J, Tverdy G & Wanson M (1955) Encephalitis in loa-loa filariasis. Journal of Neurology, Neurosurgery & Psychiatry 18, 103-119.
30. Wahl G & Georges AJ (1995) Current knowledge on the epidemiology, diagnosis, immunology, and treatment of loiasis. Tropical Medicine & Parasitology 46, 287-291.
31. Workneh W, Fletcher M & Olwit G (1993) Onchocerciasis in field workers at Baya Farm, Teppi Coffee Plantation Project, southwestern Ethiopia: prevalence and impact on productivity. Acta Tropica 54, 89-97.
32. World Health Organization (1987) Onchocerciasis and its Control: Report of a WHO Expert Committee on Onchocerciasis, Technical Report Series No. 752. WHO, Geneva.
33. World Health Organization (1995) Onchocerciasis and its Control: Report of a WHO Expert Committee on Onchocerciasis Control, Technical Report Series No. 852. WHO, Geneva, pp. 1-45.
34. World Health Organization (1999) Cameroun en bref. WHO, Yaoundé.